FDA approves new use for AbbVie’s Viekira Pak

SILVER SPRING, Md. — The Food and Drug administration have approved AbbVie’s Viekira Pak for use without ribavirin to treat certain patients with hepatitis C.

 

The new indication for Viekira Pak (ombitasvir, paritaprevir and ritonavir tablets; dasabuvir tablets) will allow it to be used for patients with genotype 1b chronic hepatitis C and compensated cirrhosis. 

 

“We are constantly striving to advance clinical care for patients living with chronic hepatitis C,” Dr. Michael Severino, EVP research and development and chief scientific officer at AbbVie, said. “This approval is especially significant because patients with chronic HCV with compensated cirrhosis are among the tough to treat, and in our study VIEKIRA PAK demonstrated 100 percent cure rates in GT1b patients without the use of ribavirin.”